Explore 3 Stock Ideas & Industry Insights Download Free Report

News

NeoVolta Posts $7.7M Net Loss in Q1 Fiscal 2027

NeoVolta, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026, reporting financial results for the first quarter of its fiscal year 2027.

Shwetambri Chauhan | 13 November 2026

CV Sciences Posts Q3 2026 Net Loss of $93K on $3M Sales

CV Sciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting third-quarter net product sales of $3,028 thousand and a net loss of $93 thousand.

Nitish Kishor | 13 November 2026

Smartbird CEO Carlsten Issues Shareholder Letter Nov. 13

Smartbird, Inc. filed a Form 8-K on November 13, 2026, reporting a shareholder letter from CEO Nadia Carlsten and a press release announcing secured data center capacity to accelerate AI infrastructure deployment.

Anjali Anand | 13 November 2026

York Space Systems Files Q3 2026 10-Q for September 30 Period

York Space Systems Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 13, 2026, covering the fiscal quarter ended September 30, 2026.

Aakashdeep | 13 November 2026

LaFayette Acquisition Corp. Q3 2026: Trust Account Reaches $118.9M

LaFayette Acquisition Corp. filed its Form 10-Q for the quarter ended September 30, 2026, with the SEC on November 13, 2026, reporting net income of $935,375 for the three-month period and marketable securities held in Trust of $118,913,115.

Aakashdeep | 13 November 2026

Nektar Therapeutics Q3 2026 10-Q: September 30 Quarter

Nektar Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026.

Vinay Lochav | 13 November 2026

OneIM Acquisition Corp. Reports Q3 2026 Financials

OneIM Acquisition Corp. filed its Form 10-Q for the quarter ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026, covering results for both the three and nine months ended on that date.

Aakashdeep | 13 November 2026

Bolt Biotherapeutics Q3 2026: Net Loss $4.4M, Cash at $13.8M

Bolt Biotherapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 13, 2026, disclosing a net loss of $4.422 million for the third quarter and an accumulated deficit of $480.328 million.

Vinay Lochav | 13 November 2026

Nektar Reports $952.9M Cash, Runway Into Q3 2028

Nektar Therapeutics filed a Form 8-K on November 13, 2026, disclosing via Regulation FD that the company held $952.9 million in cash and investments in marketable securities as of September 30, 2026, and expects that balance to extend its cash runway into the third …

Nitish Kishor | 13 November 2026

Silence Therapeutics Q3 2026: Cash Jumps to $247.7M

Silence Therapeutics plc filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the fiscal quarter ended September 30, 2026, and disclosing a significant increase in cash and cash equivalents alongside a pending acquisition by Merck KGaA, Darmstadt, Germany.

Nitish Kishor | 13 November 2026
Support

Hi! How can we help you today?

Loading…